Abstract 4121: Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody

Fu Li, Jingrong Li, Ke Yin, Juan Zhang, Zhenhu Li, Lü Liang, Yuanwu Bao, Dan Pu, Zhen Qin, Zheng Yong, Baotian Yang, Xinzhong Jon WangClinical 2019 · DOI

Abstract

Background: The programmed cell death protein 1 receptor (PD-1) is an immune-checkpoint protein that negatively regulates the immune system to avoid collateral damage to self-tissues. Tumors hijack this mechanism as a way to avoid immune detection and destruction. Presently, the FDA has approved three anti-PD-1 antibodies for the treatment in more than ten cancer types. CS1003 is a novel anti-PD-1 mAb recognizing a unique epitope developed to disrupt the PD-1 interaction with PD-L1/PD-L2 to restore or improve T-cell function as stand-alone therapy or in combination with other approaches.Methods: A panel of rat PD-1 mAbs were generated through conventional hybridoma technology. Several mAbs with favorable characteristics were further humanized. CS1003, a humanized, hinge-stabilized IgG4 mAb, was selected as our lead candidate for further characterization including antigen binding, biophysical properties as well as functional characterization.Results: CS1003 binds mouse, cynomolgus monkey and human PD-1 with similar affinity. CS1003 bound PD-1-expressing cell lines and chronically-activated T cells, blocked PD-1 interactions with PD-L1/PD-L2, resulting in inhibition of PD-1 signaling, and enhanced T cell cytokine secretion and proliferation to levels comparable to those observed with nivolumab or pembrolizumab reference molecules. CS1003 showed significantly anti-tumor activity in conventional MC38 as well as in hPD-1 knock-in mice. CS1003 showed no unexpected cross-reactivity in human tissues, with specific staining observed primarily in lymphocytes of lymphoid organs. In a pharmacokinetic (PK) study in cynomolgus monkeys following single intravenous administration at multiple dose levels, PK properties were linear with the proportionally increasing exposures from 2-18 mg/kg. In a repeated-dose toxicity study, CS1003 was well tolerated in cynomolgus monkeys and the major finding was mononuclear infiltration in multiple organs, which was consistent with its pharmacologic activity. CS1003 demonstrated a favorable safety profile with the highest non-severely toxic dose (HNSTD) of 100 mg/kg.Conclusion: CS1003 is a novel anti-PD-1 mAb with favorable preclinical characteristics and safety profile in cynomolgus monkeys. The unique feature of CS1003 is its cross-reactivity with both human and murine PD-1. This should greatly facilitate further evaluation its potential for combination therapy in various syngeneic mouse tumor models. A phase I study for CS1003 is being conducted to evaluate the safety, tolerability, PK and anti-tumor activity in patients with advanced tumors [NCT03475251].Citation Format: Fu Li, Jingrong Li, Ke Yin, Juan Zhang, Zhenhu Li, Liang Lu, Yuanwu Bao, Dan Pu, Zhen Qin, Yong Zheng, Baotian Yang, Jing Li, Xinzhong Jon Wang. Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4121.
BibTeX
@inproceedings{li2019abstract,
  author = {Fu Li and Jingrong Li and Ke Yin and Juan Zhang and Zhenhu Li and Lü Liang and Yuanwu Bao and Dan Pu and Zhen Qin and Zheng Yong and Baotian Yang and Jing Li and Xinzhong Jon Wang},
  title = {{Abstract 4121: Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody}},
  booktitle = {Clinical},
  year = {2019},
  doi = {10.1158/1538-7445.sabcs18-4121},
}

Loading related content...

Figure